Skip to content

    Research Use Only

    This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.

    🔬 100K+ researchers trust BodyHackGuide — Join r/BodyHackGuide
    RecoveryPreclinical

    Vilon Dosage Guide: Protocols, Calculator & Safety

    Everything you need to know about Vilon dosing — protocols, safety, and where to buy.

    Dose Range

    10 mg oral capsule, 1-2 daily for 10-30 days

    Dosage Calculator

    Calculate exact dosing for Vilon.

    Dosing Protocols

    Beginner

    A beginner Vilon protocol is conservative and emphasizes establishing baseline before cycling. Most beginners are older adults with general immune concerns rather than specific diagnosed immune disease. Before any Vilon cycle, complete a baseline assessment:

    Annual physical with primary care including review of all medications and supplements.

    Baseline labs: complete blood count with differential (CBC with differential), basic metabolic panel (BMP), comprehensive metabolic panel (CMP) including liver and kidney function, fasting lipid panel, fasting glucose and HbA1c, TSH, vitamin D 25-OH, B12, folate, ferritin, hs-CRP. These are the labs to track for any general wellness and immune-relevant self-experiment.

    Vaccination status review: ensure influenza for the current season, COVID-19 per current guidelines, pneumococcal if age-appropriate (PPSV23 at 65+ or PCV20 in series), shingles (Shingrix) at 50+, Tdap within 10 years, and any other vaccines appropriate to risk.

    Chronic disease review: diabetes control (HbA1c under 7), hypertension control (under 130/80), hyperlipidemia appropriately managed, sleep apnea treated if diagnosed, smoking cessation if relevant, alcohol within recommended limits.

    Lifestyle baseline: sleep 7 to 9 hours, exercise plan in place, Mediterranean or DASH dietary pattern, body composition in reasonable range.

    With this baseline in hand, the beginner Vilon cycle is: 1 capsule (20 mg nominal, approximately 2 to 4 mg peptide) on an empty stomach each morning with water for 10 consecutive days. Wait 60 to 90 days. Then optionally repeat, up to 2 cycles in the first year.

    During the 10-day cycle, keep a simple log: daily energy (1 to 10), overall wellbeing (1 to 10), any signs of infection (sore throat, runny nose, cough, fatigue), wound healing if applicable, and any unusual symptoms (joint aches, rash, gastrointestinal changes).

    After the first cycle, observe for 30 to 60 days before drawing any conclusions. If the user tolerated the cycle without adverse events and wants to continue exploring, a second cycle 60 to 90 days after the first is appropriate.

    Repeat baseline labs 3 to 6 months after starting the Vilon exploration to compare. A modest reduction in hs-CRP, a modest improvement in CBC differential parameters (normalization of lymphocyte counts if initially low, for example), or a subjective improvement in recovery from minor illnesses are the kinds of changes to look for. Do not expect dramatic shifts.

    Beginner users should not combine Vilon with other new peptides or new supplements starting at the same time. Run Vilon as a solo new variable so any observed change can be interpreted.

    Do not use Vilon during active infection, during active cancer therapy, during active autoimmune flare, during immunosuppression for any reason, during pregnancy, during breastfeeding, or in the week before or after surgery. These are appropriate cautions for any new immune-modulatory intervention.

    Stop the cycle immediately if any of the following occur: new or worsening autoimmune symptom (joint pain, rash, eye pain, gastrointestinal symptoms suggestive of IBD), symptoms suggesting infection reactivation (rash on one side of the torso suggestive of shingles, new genital lesions suggestive of herpes), signs of allergic reaction (hives, itching, lip or tongue swelling, breathing difficulty), or unexplained fever, bruising, or bleeding. These should trigger medical evaluation.

    Standard

    An intermediate Vilon protocol assumes the user has completed at least one conservative cycle with documented labs and symptom logs, has tolerated the peptide, and wants to extend the experiment with layered optimization or exploration of the broader Khavinson framework.

    Intermediate cycle: 2 capsules (40 mg nominal, approximately 4 to 8 mg peptide) daily, split morning and early afternoon on an empty stomach, for 10 consecutive days. Wait 60 to 90 days. Repeat up to 3 times per year.

    Intermediate users may layer additional Khavinson peptides across cycles. A common rotation: Cycle 1 Vilon (immune); Cycle 2 Epitalon (pineal/circadian); Cycle 3 Pinealon (cognitive); Cycle 4 Vilon again. This distributes bioregulator exposure across 3 cardinal axes (immune, pineal, cognitive) over the year. More aggressive rotations add Cardiogen (cardiac), Vesugen (vascular), Thymogen (immune second generation), or others as the user's specific goals dictate.

    Between cycles, maintain an evidence-graded baseline immune support stack:

    Core supplements: vitamin D to target serum 40 to 60 ng/mL (typically 2000 to 5000 IU daily); zinc 15 to 30 mg daily; selenium 100 to 200 mcg daily; magnesium glycinate 300 to 400 mg at bedtime; omega-3 EPA+DHA 2 to 4 g daily; vitamin C 500 to 1000 mg daily.

    Protein and muscle support (because skeletal muscle is an important immune-active organ in aging): adequate dietary protein (1.2 to 1.6 g/kg/day for older adults), with emphasis on distributing protein across meals; creatine monohydrate 5 g daily; resistance training 2 to 3 times per week.

    Sleep optimization: consistent schedule, limit alcohol near bedtime, limit caffeine after noon, dark and cool bedroom, screen hygiene, and consider magnesium and melatonin (0.5 to 3 mg) if sleep initiation is challenging. Treat diagnosed sleep apnea.

    Vaccination maintenance: annual influenza, COVID-19 per current guidelines, pneumococcal (PPSV23 at 65+ or PCV20 in series), shingles (Shingrix), Tdap every 10 years.

    Chronic disease optimization: HbA1c, blood pressure, lipid, and weight targets per standard guidelines.

    Monitoring during intermediate phase: CBC with differential, BMP, CMP, lipid panel, HbA1c, hs-CRP, vitamin D every 6 to 12 months. Consider adding T-cell subset analysis (CD3, CD4, CD8, CD19, NK cells by flow cytometry) annually if the user has access to a lab offering it and is genuinely interested in objective immune markers. Consider annual shingles surveillance in older adults.

    Intermediate users should develop a clearer sense of whether Vilon (and potentially other Khavinson peptides) is generating a reproducible benefit. After 3 cycles with documented labs and symptom logs, if no detectable biochemical response and no consistent symptomatic benefit emerges, the honest conclusion is that Vilon is not meaningfully contributing for this user. Continuing indefinitely is opportunity cost.

    If the user is producing a detectable response (modest hs-CRP reduction, modest lymphocyte subset improvement, modest subjective improvement in infection recovery or wound healing) and no adverse signals, continuing with 2 to 3 cycles annually is reasonable.

    Intermediate users should specifically watch for unintended autoimmune or infection-reactivation signals. New joint pain, new rash, new eye inflammation, new gastrointestinal symptoms, unexplained weight loss, unexplained fevers, or rash on one side of the torso (possible shingles reactivation) should prompt cycle cessation and medical evaluation.

    Intermediate users considering injectable rather than oral Vilon should understand that the injectable route is research-chemical territory. The evidence does not support injectable Vilon as superior to oral in any outcome a user can measure. The conservative recommendation remains oral capsule use.

    Advanced

    An advanced Vilon protocol is appropriate only for users who have multiple documented cycles behind them, stable labs, a working clinician relationship, a clear self-experimental goal, and genuine interest in the Khavinson framework. Most users do not need an advanced protocol. The incremental benefit over intermediate cycling is small.

    Advanced cycle: 2 to 3 capsules daily (40 to 60 mg nominal, approximately 4 to 12 mg peptide), split morning and afternoon, for 10 consecutive days. Wait 60 to 90 days. Up to 4 cycles per year.

    Advanced users sometimes run multi-peptide Khavinson stacks within a single cycle — Vilon plus Epitalon, Vilon plus Thymogen, or larger combinations. This is self-experimental and lacks randomized trial support over single-peptide cycling.

    At the advanced level, the user should have defined thresholds for whether Vilon is generating enough benefit to continue. Realistic thresholds: reproducible modest hs-CRP reduction across cycles that is not explained by concurrent lifestyle changes; reproducible modest T-cell subset improvement on flow cytometry if measured; reproducible reduction in minor infection burden (fewer or shorter respiratory infections per year); reproducible improvement in wound healing time or recovery from minor illness; absence of safety signals.

    If these thresholds are missed across 4 to 6 cycles with adequate measurement, the advanced user should stop cycling and reconsider the evidence-based alternatives. For many users, the highest-impact additional intervention is something other than continued Vilon — tighter sleep discipline, weight loss, GLP-1 agonist therapy in appropriate candidates, intensified exercise programming, treatment of underlying chronic disease, or specific immune therapies where indicated.

    Advanced users pairing Vilon with immune checkpoint inhibitors, CAR-T cell therapy, or other advanced immune cancer therapies should not proceed without oncology specialist input. The theoretical interaction is too important to experiment with.

    Advanced users on biologic therapy for autoimmune disease (anti-TNF, anti-IL-17, JAK inhibitors, anti-CD20, etc.) should consult with their rheumatologist, dermatologist, gastroenterologist, or neurologist (whichever is managing the biologic) before cycling Vilon. The theoretical interference with intended immunosuppression is a legitimate concern.

    Advanced users considering Vilon during active infection, active cancer treatment, or perioperative period should defer. These are settings in which immune state is already being actively managed.

    Monitoring at advanced level: CBC with differential, BMP, CMP, lipid panel, HbA1c, hs-CRP, vitamin D, ferritin, TSH every 3 to 6 months. T-cell subset flow cytometry annually if available. Cancer screening per age-appropriate guidelines (colonoscopy, mammography, low-dose chest CT for smokers, PSA in select men, cervical screening). Dermatologic screening annually in older adults or those with skin cancer risk factors. Annual dental exam.

    Advanced users should maintain a comprehensive health review annually with their primary care physician, including discussion of bioregulator cycling. The goal is ongoing calibration of whether the exploration is generating benefit, whether any new condition warrants cessation, and whether alternative interventions would be higher-yield.

    The strongest answer at every advanced level remains: vaccinations, evidence-based lifestyle, evidence-based chronic disease management, age-appropriate cancer and health screening, and a strong clinician relationship — and then, optionally, Vilon as an experimental adjunct within the Khavinson bioregulator framework. Vilon is not a sufficient immune health strategy. It is at best a minor complement to a real strategy.

    Commonly Stacked With

    Vilon stacking decisions depend on the user's goal. The first question is always: is the evidence-based immune foundation in place?

    Evidence-based immune foundation:

    • Vaccinations appropriate to age: annual influenza, COVID-19 boosters per current guidelines, pneumococcal (PPSV23 and PCV13/PCV20 per age), shingles (Shingrix for adults 50+), Tdap every 10 years, HPV vaccination through age 45 if eligible, hepatitis B if not previously immunized.
    • Sleep: 7 to 9 hours nightly. Sleep deprivation is a large and well-characterized immune suppressor.
    • Exercise: 150+ minutes moderate or 75+ minutes vigorous aerobic per week, plus 2 to 3 resistance sessions.
    • Nutrition: adequate protein (1.2 to 1.6 g/kg/day for older adults), Mediterranean or DASH dietary pattern, adequate fruits and vegetables for micronutrient sufficiency.
    • Weight: BMI in healthy range, waist circumference under 40 inches for men, under 35 for women. Obesity is a substantial immune dysregulator.
    • Alcohol: under 1 to 2 standard drinks per day for men, 0 to 1 for women. Heavy alcohol is immunosuppressive.
    • Smoking cessation: smoking substantially impairs mucosal immunity and increases respiratory infection risk.
    • Vitamin D: target serum 30 to 60 ng/mL, typically with 2000 to 5000 IU daily supplementation.
    • Zinc: 15 to 30 mg daily (dietary plus supplement if intake is low).
    • Selenium: 100 to 200 mcg daily (dietary plus supplement if intake is low).
    • Chronic disease control: diabetes with HbA1c under 7 percent, hypertension under 130/80, hyperlipidemia addressed with statin when indicated. Poorly controlled chronic disease is a major immune dysregulator.
    • Stress management: chronic psychological stress is immunosuppressive.
    • Routine health maintenance: annual physical, age-appropriate cancer screening, dental care, primary care relationship.

    That is the foundation. Vilon does not substitute for any of it. It can be considered as an experimental adjunct on top.

    For users whose primary goal is age-related immune decline support (immunosenescence concerns in the 60-plus age range without specific diagnosed immune disease), a standard Vilon cycle (1 to 2 capsules daily for 10 days, 2 to 4 times per year) layered onto the foundation above is a reasonable low-stakes experiment. Track subjective markers (winter respiratory infections, wound healing time, recovery from minor illness) and objective markers where available (CBC with differential, annual inflammatory markers like hs-CRP). Do not expect dramatic change; expect modest-to-no detectable difference.

    For users interested in Khavinson anti-aging framework, Vilon is commonly cycled alongside Epitalon, which targets the pineal axis. The theoretical pairing is "pineal-thymic axis" support. Practical protocol: Vilon cycle followed 30 days later by Epitalon cycle, alternating through the year for 4 total cycles (2 Vilon and 2 Epitalon). Users who want broader coverage add Pinealon for cognitive support, Vesugen for vascular support, or other Khavinson peptides across the annual calendar.

    Vilon and Thymogen are both claimed as thymic immune bioregulators but they differ in sequence (Vilon = KE dipeptide, Thymogen = EW dipeptide). They are often considered redundant. Users who want to explore the thymic axis more deeply may alternate between them across cycles rather than running both simultaneously.

    Vilon with oral amino acid supplementation (BCAA, glutamine, lysine, glutamate): no documented interaction, no special concern.

    Vilon with multivitamin, mineral supplementation, vitamin D, omega-3: no interaction, routine coexistence.

    Vilon with creatine, protein powder, collagen: no interaction.

    Vilon with popular immune-adjacent supplements (elderberry, echinacea, zinc lozenges, quercetin, NAC, beta-glucan, medicinal mushrooms like reishi, turkey tail, lion's mane): no documented interactions, but the evidence base for most of these is also thin. Layering many weakly-evidenced immune supplements is unlikely to compound into a large effect; it mostly compounds cost.

    Vilon with evidence-based adaptogens (rhodiola, ashwagandha): no interaction. Ashwagandha has a more substantial evidence base for modest subjective wellbeing and stress-cortisol effects than Vilon does for its immune claims, and is probably a more impactful addition to an anti-aging stack for most users.

    Vilon with nootropic or cognitive compounds: no interaction. Users specifically focused on cognitive concerns should consider Pinealon or Semax before Vilon.

    Vilon with semaglutide, tirzepatide, retatrutide, or other GLP-1/dual agonists: no direct interaction. Weight loss from GLP-1 therapy has substantial immune-functional benefits (reduced obesity-related inflammation, improved metabolic markers), which are likely larger than any Vilon effect.

    Vilon with testosterone replacement therapy, clomiphene, or enclomiphene: no direct interaction.

    Vilon with statins, antihypertensives, antiplatelets, anticoagulants: no direct interaction expected.

    Injection of Vilon alongside other injectable peptides (BPC-157, TB-500, Ipamorelin, Sermorelin, Tesamorelin, CJC-1295, etc.): no direct interaction with the Vilon compound itself, but each peptide should be drawn and injected separately rather than mixed in one syringe.

    Cross-family Khavinson stacking: the most common multi-Khavinson stack including Vilon is Vilon + Epitalon (pineal-thymic axis), sometimes extended to Vilon + Epitalon + Pinealon (adding cognitive), or Vilon + Epitalon + Vesugen + Cardiogen (adding vascular-cardiac for older adults). These are all self-experimental.

    The cleanest advice for most users: pick a single Khavinson peptide to cycle for one year, document carefully, and only add a second if you have a genuine reason. Running 4 to 6 bioregulators simultaneously dilutes interpretation and is rarely necessary.

    Side Effects & Safety

    Published Khavinson-group observations describe Vilon as exceptionally well tolerated at oral doses of 1 to 2 capsules daily during 10-day cycles. The structural simplicity of the dipeptide — lysine and glutamate, both ubiquitous amino acids — and the low absolute peptide quantity per capsule (2 to 4 mg) make acute toxicity essentially zero. Specific adverse events reported in small cohorts include occasional mild nausea or gastrointestinal discomfort (rare), infrequent transient headache (rare), and rare mild injection site reactions when the injectable form is used. Serious adverse events attributable to Vilon are not documented in the published literature. That short-term safety profile is reassuring, but the usual caveats about limited Russian trial evidence apply. The cohorts are small, the follow-up is measured in weeks to months, and placebo controls are uncommon. Rare serious adverse events requiring tens of thousands of patient-years to detect — autoimmune provocation, lymphoproliferative disorder, inadvertent oncogenic stimulation in a patient with latent malignancy, bleeding or thrombotic effects — cannot be ruled in or out from the available data. "Well tolerated in small trials" is not the same as "safe for long-term unsupervised use in all populations." Theoretical concerns specific to Vilon's proposed mechanism deserve explicit discussion. The most important theoretical concern is interaction with active autoimmune disease. Vilon is claimed to support T-cell maturation, peripheral lymphocyte balance, and NK cell activity. In a patient with active autoimmune disease — rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, psoriasis, ankylosing spondylitis — any intervention that modulates T-cell function carries a theoretical concern about disease flare. The published data do not document Vilon-triggered autoimmune flare, but the data base is too small to detect a rare event. A patient with active autoimmune disease on biologic or DMARD therapy should not initiate Vilon without rheumatology or relevant specialist input. The second theoretical concern is interaction with active cancer therapy. Cancer treatment often involves careful manipulation of immune state — chemotherapy with myelosuppression, immune checkpoint inhibitor therapy that itself modulates T-cell function, radiation therapy with local immune effects, stem cell transplantation with elaborate immune reconstitution protocols. Introducing Vilon as an uncharacterized additional immune variable during active cancer therapy is not advisable. Patients who are in active cancer treatment should consult their oncologist before starting any peptide bioregulator. The third theoretical concern is interaction with post-transplant immunosuppression. Solid organ transplant recipients (kidney, liver, heart, lung) are on strict immunosuppressive regimens (tacrolimus, cyclosporine, mycophenolate, steroids) designed to prevent graft rejection. A peptide that theoretically enhances T-cell function could destabilize that carefully balanced state. Transplant patients should not initiate Vilon without their transplant specialist's input. The fourth theoretical concern is inadvertent provocation of latent viral infection or reactivation. Many older adults carry latent herpes zoster (varicella zoster), herpes simplex, Epstein-Barr, cytomegalovirus, and tuberculosis. Immune modulation can in principle tip latent-to-active transitions in either direction. The published Vilon data do not describe reactivation events, but the monitoring was not specifically designed to detect them. Allergic reactions to peptide therapeutics are rare but possible. Hives, itching, lip or tongue swelling, or breathing difficulty after a dose warrant immediate cessation and medical attention. The oral capsule excipient matrix includes milk-protein isolates and starch, which matter for patients with lactose intolerance or milk allergy. Injection site reactions for the injectable form include transient redness, mild swelling, and occasional bruising. These are common with any subcutaneous peptide and are not unique to Vilon. Drug interaction data for Vilon are effectively non-existent in Western literature. Theoretical interactions of concern include: - Immunosuppressants (tacrolimus, cyclosporine, sirolimus, mycophenolate, methotrexate, azathioprine, steroids): theoretical reduction in net immunosuppression; avoid. - Biologics (anti-TNF agents, anti-IL-17, anti-IL-23, JAK inhibitors, anti-CD20, etc.): theoretical interference with intended immune suppression; avoid without specialist input. - Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab, atezolizumab, durvalumab, cemiplimab): theoretical potentiation or destabilization of immune activation; avoid during active therapy. - Chemotherapy: avoid during active cycles without oncology input. - Radiation therapy: avoid during active treatment. - Standard vaccinations: no known interaction; Vilon cycling does not interfere with vaccine efficacy in the published data, but best practice is to separate peptide cycling from vaccination by at least a week in either direction. - Antibiotics, antivirals, antifungals: no known interaction. - Anticoagulants and antiplatelets: no known interaction. Pregnancy and breastfeeding: Vilon is not recommended. The data for peptide bioregulators in pregnancy are essentially absent and prudent avoidance is the default. Children and adolescents: Vilon is not intended for pediatric use. Immune development in children follows specific trajectories that should not be experimentally modulated. Long-term safety data beyond a year or two of repeated cycling do not exist in published form. A user cycling Vilon for multiple years should maintain annual comprehensive health reviews including CBC with differential, basic metabolic panel, and screening appropriate to age and risk. Any new immune-relevant condition (infection, malignancy, autoimmune symptom) during a Vilon cycling program warrants evaluation and likely suspension. The most common real-world "side effect" of Vilon use is opportunity cost. A user who buys Vilon, cycles it, notices no objective change, and concludes peptides don't work for them has often bypassed the evidence-based immune interventions — timely vaccination, sleep optimization, exercise, weight management, alcohol reduction, smoking cessation, vitamin D sufficiency. Framed that way, the worst side effect of Vilon is delaying or displacing actually effective immune support. A reader concerned about immune function should start with the evidence-based foundation and treat Vilon as an optional adjunct.

    Contraindications

    Absolute contraindications to Vilon include pregnancy, breastfeeding, known hypersensitivity to short-peptide bioregulators or to capsule excipients (milk-protein isolates, starch), active critical illness, active hematologic malignancy undergoing chemotherapy or targeted therapy, active solid cancer on active treatment, active immune checkpoint inhibitor therapy, active post-transplant immunosuppression, active autoimmune disease on biologic therapy, active acute infection requiring medical treatment, and the week before and after any scheduled surgical procedure. Any of these is a reason not to start Vilon. Relative contraindications — reasons to defer Vilon until the issue is clarified — include: history of autoimmune disease in remission off therapy (possible flare risk with immune modulation); history of cancer with current surveillance (any new unexplained symptom during peptide cycling should trigger workup rather than be attributed to the peptide); history of recurrent infections warranting specialist evaluation before introducing new immune variables; known latent tuberculosis without prior treatment; hematologic disorders (thrombocytopenia, neutropenia, anemia of unclear etiology) pending evaluation; chronic viral hepatitis B or C pending hepatology input; HIV infection on antiretroviral therapy (consult with infectious disease specialist); pregnancy planning in next few months. Age considerations: Vilon is intended for adults, primarily older adults with age-related immune concerns. It is not intended for children or adolescents. Younger adults (under 40) without specific indications typically do not need bioregulator peptides. Cardiovascular disease: Vilon has no documented cardiovascular effect and no specific cardiovascular contraindication. Users on cardiovascular medications (antihypertensives, statins, antiplatelets, anticoagulants) can cycle Vilon without direct drug interaction concern. Diabetes: no specific contraindication. Users with diabetes should ensure glucose control is optimized before introducing any new supplement. Kidney disease: no dose adjustment data. Users with eGFR below 30 should consult with their nephrologist before initiating. Liver disease: no dose adjustment data. Users with cirrhosis or advanced hepatic impairment should defer pending hepatology input. Thyroid disease: no specific contraindication. Ensure thyroid status is optimized before attributing any response to a peptide. Adrenal disease: no specific contraindication. Users on replacement glucocorticoids should continue their prescribed regimen. Autoimmune disease: this is the most important contraindication category for Vilon specifically. Active autoimmune disease (RA, SLE, MS, IBD, psoriasis, ankylosing spondylitis, type 1 diabetes, autoimmune thyroiditis, vasculitis, etc.) on biologic or DMARD therapy is a relative-to-absolute contraindication depending on the specific condition and treating specialist's judgment. Autoimmune disease in remission off therapy warrants specialist discussion before initiation. Do not assume immune modulation is beneficial in autoimmune disease; the direction of effect is unpredictable. Cancer history: users with active cancer under treatment should not initiate Vilon. Users in cancer remission should discuss with oncologist. Users with concerning symptoms (unexplained weight loss, night sweats, prolonged fevers, bone pain, unusual lumps) should prioritize workup over supplementation. Transplant status: solid organ transplant recipients on immunosuppression should not initiate Vilon without their transplant specialist's input. HIV status: users on effective antiretroviral therapy with undetectable viral load and adequate CD4 count may consult with their infectious disease specialist about whether Vilon cycling is appropriate. Users with uncontrolled HIV should not cycle. Active infection: defer Vilon during acute systemic infection. Standard infection treatment takes priority. Drug interactions: - Vaccines: no known interaction, but best practice is to separate Vilon cycling from vaccination by at least 1 week in either direction. - Immunosuppressants: avoid. Theoretical interference with intended immunosuppression. - Biologics (TNF, IL, JAK, CD20 directed agents): avoid without specialist input. - Immune checkpoint inhibitors: avoid during active therapy. - Chemotherapy: avoid during active cycles without oncology input. - Radiation therapy: avoid during active treatment. - Antiretrovirals: no known interaction but consult infectious disease specialist for HIV-positive users. - Antibiotics, antivirals, antifungals: no known interaction. - Antiplatelets, anticoagulants: no known interaction. - Cardiovascular medications (statins, antihypertensives): no known interaction. - Diabetes medications (metformin, SGLT2 inhibitors, GLP-1 agonists, insulin): no known interaction. - Hormone replacement (TRT, HRT, thyroid replacement): no known interaction. - Psychotropics (SSRIs, SNRIs, benzodiazepines, stimulants): no known interaction. - Pain medications (NSAIDs, acetaminophen, opioids): no known interaction. Pregnancy and breastfeeding: Vilon is not recommended. Data are essentially absent and prudent avoidance is the default. Surgery and perioperative period: discontinue at least 1 week before any scheduled surgery and do not resume until 1 week after, or longer based on surgeon's guidance. Anesthesia: inform anesthesiologists about all supplements and peptides. Vilon should be included in preoperative medication review. Imaging and procedures: Vilon has no known interaction with contrast imaging, colonoscopy, endoscopy, or other routine procedures. Operating machinery, driving: no documented cognitive or reaction-time effect. Vilon is not expected to impair. Alcohol: no direct interaction but chronic heavy alcohol is immunosuppressive and works against immune goals. Cannabis: no direct interaction. Long-term use: no published data beyond a year or two of repeated cycling. Users cycling Vilon for multiple years should maintain annual complete health reviews and adjust based on documented benefit and safety.

    Check interactions with the Interaction Checker →

    Additional Notes

    Commercial Vilon capsules contain 20 mg of total powder per capsule, with approximately 2 to 4 mg of the synthetic Lys-Glu dipeptide and the balance as milk-protein and starch excipients. The 20 mg label refers to total powder, not peptide dose. This is consistent across the Khavinson oral bioregulator line.

    Standard oral dosing in Khavinson-group observations has been 1 to 2 capsules daily for 10 consecutive days, cycled with a 60 to 90 day washout. Dose timing is typically morning on an empty stomach with water, 15 to 30 minutes before food. If a second capsule is taken, it is usually given in the early afternoon between meals.

    There is no dose-ranging data to support advanced oral dosing above 2 capsules per day. Users cycling 3 or 4 capsules daily are operating beyond the published observational data. Empirical reports on vendor forums suggest no consistent additional benefit at higher doses.

    Injectable Vilon is available through research-chemical channels. The typical injectable protocol is 50 to 200 mcg subcutaneously daily during a 10 to 20 day cycle. Injectable dosing has somewhat more published use in Russian clinical literature than some other Khavinson peptides because Vilon is one of the oldest compounds in the line. Nonetheless, for Western users without clinical oversight, the conservative recommendation remains oral capsule use.

    Cycling convention is 10-days-on / 60-to-90-days-off per the standard Khavinson framework. The rationale for this specific pattern is theoretical: Khavinson proposes that the short cycle is sufficient to reset gene expression patterns and that the washout allows the reset effect to consolidate. There is no direct evidence comparing 10-day cycles with 20-day cycles, 30-day cycles, or continuous dosing. Most users do 2 to 4 cycles per year.

    Dose for different immune goals (immunosenescence support vs. post-illness recovery vs. general anti-aging) is not differentiated in published data. The same 1 to 2 capsules daily for 10 days is used regardless of goal.

    Dose for users with chronic disease: no established adjustment. Users with diabetes, hypertension, hyperlipidemia, or other stable chronic diseases follow the same 1 to 2 capsules daily. Users with active autoimmune disease on biologics, active cancer therapy, or post-transplant immunosuppression should not initiate Vilon without specialist input regardless of dose.

    Storage: capsules kept in a cool dry place out of direct sunlight. Refrigeration not required for sealed bottles but extends shelf life once opened. Shelf life typically 24 months from manufacture for sealed bottles. Discard if color, odor, or appearance change.

    Missed doses during a cycle: skip the missed dose, resume next day. Do not double up. A cycle interrupted by more than 2 missed days is best terminated and restarted fresh after the standard washout.

    Interaction with food: oral bioavailability is thought to be modestly better on an empty stomach. Taking with food reduces peak concentration but does not eliminate absorption.

    Interaction with alcohol: no direct interaction data. A 10-day cycle is short enough that abstaining from alcohol is trivial. Chronic alcohol is immunosuppressive independently.

    Dose for users over 80: not specifically studied but the same 1 to 2 capsules daily is used. Elderly users should pay additional attention to polypharmacy and drug interactions.

    Dose for users under 40: the Khavinson framework is oriented to age-related immune decline. Younger adults without specific indications generally do not need Vilon. Immune concerns in younger adults should prompt standard workup (CBC, inflammatory markers, infectious disease screening as indicated, autoimmune panel if symptomatic) rather than self-administration of a bioregulator.

    Dose for pregnancy or breastfeeding: not recommended. No data.

    Dose for children and adolescents: not recommended. No data, and pediatric immune development should not be experimentally modulated.

    Timing with vaccination: no known interaction, but best practice is to separate Vilon cycling from vaccination by at least one week in either direction to allow interpretation of vaccine response and any potential peptide effect independently.

    Timing with surgery: discontinue at least 1 week before scheduled surgery and do not resume until at least 1 week after, or longer based on surgeon's guidance. This is a general precaution for any immune-active compound.

    Frequently Asked Questions

    What is the recommended Vilon dosage?

    The typical dose range for Vilon is 10 mg oral capsule, 1-2 daily for 10-30 days. Always start with the lowest effective dose.

    How often should I take Vilon?

    Administration frequency depends on the specific protocol. Consult current research literature.

    Does Vilon need to be cycled?

    Cycling requirements depend on the protocol. Follow established research guidelines.

    What are Vilon side effects?

    Published Khavinson-group observations describe Vilon as exceptionally well tolerated at oral doses of 1 to 2 capsules daily during 10-day cycles. The structural simplicity of the dipeptide — lysine and glutamate, both ubiquitous amino acids — and the low absolute peptide quantity per capsule (2 to 4 mg) make acute toxicity essentially zero. Specific adverse events reported in small cohorts include occasional mild nausea or gastrointestinal discomfort (rare), infrequent transient headache (rare), and rare mild injection site reactions when the injectable form is used. Serious adverse events attributable to Vilon are not documented in the published literature. That short-term safety profile is reassuring, but the usual caveats about limited Russian trial evidence apply. The cohorts are small, the follow-up is measured in weeks to months, and placebo controls are uncommon. Rare serious adverse events requiring tens of thousands of patient-years to detect — autoimmune provocation, lymphoproliferative disorder, inadvertent oncogenic stimulation in a patient with latent malignancy, bleeding or thrombotic effects — cannot be ruled in or out from the available data. "Well tolerated in small trials" is not the same as "safe for long-term unsupervised use in all populations." Theoretical concerns specific to Vilon's proposed mechanism deserve explicit discussion. The most important theoretical concern is interaction with active autoimmune disease. Vilon is claimed to support T-cell maturation, peripheral lymphocyte balance, and NK cell activity. In a patient with active autoimmune disease — rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, psoriasis, ankylosing spondylitis — any intervention that modulates T-cell function carries a theoretical concern about disease flare. The published data do not document Vilon-triggered autoimmune flare, but the data base is too small to detect a rare event. A patient with active autoimmune disease on biologic or DMARD therapy should not initiate Vilon without rheumatology or relevant specialist input. The second theoretical concern is interaction with active cancer therapy. Cancer treatment often involves careful manipulation of immune state — chemotherapy with myelosuppression, immune checkpoint inhibitor therapy that itself modulates T-cell function, radiation therapy with local immune effects, stem cell transplantation with elaborate immune reconstitution protocols. Introducing Vilon as an uncharacterized additional immune variable during active cancer therapy is not advisable. Patients who are in active cancer treatment should consult their oncologist before starting any peptide bioregulator. The third theoretical concern is interaction with post-transplant immunosuppression. Solid organ transplant recipients (kidney, liver, heart, lung) are on strict immunosuppressive regimens (tacrolimus, cyclosporine, mycophenolate, steroids) designed to prevent graft rejection. A peptide that theoretically enhances T-cell function could destabilize that carefully balanced state. Transplant patients should not initiate Vilon without their transplant specialist's input. The fourth theoretical concern is inadvertent provocation of latent viral infection or reactivation. Many older adults carry latent herpes zoster (varicella zoster), herpes simplex, Epstein-Barr, cytomegalovirus, and tuberculosis. Immune modulation can in principle tip latent-to-active transitions in either direction. The published Vilon data do not describe reactivation events, but the monitoring was not specifically designed to detect them. Allergic reactions to peptide therapeutics are rare but possible. Hives, itching, lip or tongue swelling, or breathing difficulty after a dose warrant immediate cessation and medical attention. The oral capsule excipient matrix includes milk-protein isolates and starch, which matter for patients with lactose intolerance or milk allergy. Injection site reactions for the injectable form include transient redness, mild swelling, and occasional bruising. These are common with any subcutaneous peptide and are not unique to Vilon. Drug interaction data for Vilon are effectively non-existent in Western literature. Theoretical interactions of concern include: - Immunosuppressants (tacrolimus, cyclosporine, sirolimus, mycophenolate, methotrexate, azathioprine, steroids): theoretical reduction in net immunosuppression; avoid. - Biologics (anti-TNF agents, anti-IL-17, anti-IL-23, JAK inhibitors, anti-CD20, etc.): theoretical interference with intended immune suppression; avoid without specialist input. - Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab, atezolizumab, durvalumab, cemiplimab): theoretical potentiation or destabilization of immune activation; avoid during active therapy. - Chemotherapy: avoid during active cycles without oncology input. - Radiation therapy: avoid during active treatment. - Standard vaccinations: no known interaction; Vilon cycling does not interfere with vaccine efficacy in the published data, but best practice is to separate peptide cycling from vaccination by at least a week in either direction. - Antibiotics, antivirals, antifungals: no known interaction. - Anticoagulants and antiplatelets: no known interaction. Pregnancy and breastfeeding: Vilon is not recommended. The data for peptide bioregulators in pregnancy are essentially absent and prudent avoidance is the default. Children and adolescents: Vilon is not intended for pediatric use. Immune development in children follows specific trajectories that should not be experimentally modulated. Long-term safety data beyond a year or two of repeated cycling do not exist in published form. A user cycling Vilon for multiple years should maintain annual comprehensive health reviews including CBC with differential, basic metabolic panel, and screening appropriate to age and risk. Any new immune-relevant condition (infection, malignancy, autoimmune symptom) during a Vilon cycling program warrants evaluation and likely suspension. The most common real-world "side effect" of Vilon use is opportunity cost. A user who buys Vilon, cycles it, notices no objective change, and concludes peptides don't work for them has often bypassed the evidence-based immune interventions — timely vaccination, sleep optimization, exercise, weight management, alcohol reduction, smoking cessation, vitamin D sufficiency. Framed that way, the worst side effect of Vilon is delaying or displacing actually effective immune support. A reader concerned about immune function should start with the evidence-based foundation and treat Vilon as an optional adjunct.

    Where can I buy Vilon?

    Visit our vendor directory to find trusted sources for Vilon.

    Free 2026 Peptide Cheat Sheet — 50 pages, PDF

    Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.

    Download Free